卵巣がん治療薬市場 - 2030年の成長予測、統計および事実

  • Report Code : TIPRE00003750
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究レポート】卵巣がん治療薬の市場規模は2022年の21億ドルから2030年までに38億ドルに成長すると予測されている。市場は、2022 ~ 2030 年に 7.7% の CAGR を記録すると推定されています。

市場洞察とアナリストの見解:

卵巣がんの発生率の上昇により、卵巣がん治療薬市場の成長が推進されています。しかし、副作用による製品リコールは市場の成長を妨げています。

成長の原動力:

卵巣がんの発生率の増加が治療選択肢の需要を促進

卵巣がんは7番目に多い。女性に多いがんであり、それぞれ子宮頸がん、子宮内膜がんに次いで 3 番目に多い婦人科悪性腫瘍です。世界卵巣がん連合の報告書によると、毎年 324,000 人の女性が卵巣がんと診断され、207,000 人の女性がこの病気で死亡しています。さらに、卵巣がんの早期発見に利用できる公的健康診断プログラムがないため、卵巣がん患者の大多数は進行期(局所進行または転移性)の状態と診断されています。したがって、卵巣がんの発生率の上昇により、効果的な治療選択肢への需要が高まっています。減量手術とプラチナベースの化学療法を組み合わせた第一選択療法は、新たに進行性卵巣がんと診断された女性に対する標準治療です。また、承認されたPARP阻害剤、オラパリブ、ルカパリブ、ニラパリブなどの治療選択肢は、新たに診断された卵巣がんの管理における画期的な選択肢です。進行卵巣がんの管理におけるPARP阻害剤の使用も、臨床転帰を改善するための効果的な治療選択肢として浮上しています。これらの阻害剤は、1 回目、2 回目、3 回目のプラチナベースの化学療法に対する完全奏効(CR)後の、新たに診断された症例に長期的な有効性と無増悪生存期間(PFS)をもたらします。

戦略的洞察< br>
レポートのセグメント化と範囲:

卵巣がん治療薬市場分析は、種類、薬剤クラス、流通チャネルのセグメントを考慮して実行されました。

セグメント分析:

種類ごとに、市場は上皮性卵巣がん、胚細胞卵巣がん、間質腫瘍に分類されます。上皮性卵巣がんセグメントは、2022 年の卵巣がん治療薬市場で最大のシェアを保持しました。同じセグメントは、予測期間中に 8.2% という最高の CAGR を記録すると予想されます。 Cancer Research UK の報告書によると、上皮性卵巣がんは最も一般的なタイプの卵巣がんです。たとえば、卵巣の腫瘍 100 個のうちほぼ 90 個 (90%) は上皮腫瘍です。悪性度の高い末期卵巣がん患者にとって、市場で利用できる治療選択肢は限られています。 2022年11月、食品医薬品局(FDA)は、上皮性卵巣がんに苦しむ成人患者を対象に、Elahere ImmunoGen, Inc.が製造する「ミルベツキシマブ ソラフタンシン・ジンクス」の承認を発表した。上皮性卵巣がん治療におけるこの薬剤候補の医師推奨用量は 6 mg/kg で、3 週間に 1 回、IV 点滴で投与されます。 2024年1月、FDAは再発上皮性卵巣がん患者の治療を目的としたメソテリン標的抗体薬物複合体(ADC)「RC88」のファストトラック指定(FTD)の承認を発表した。したがって、医薬品承認数の増加により、上皮性卵巣がんセグメントの卵巣がん治療薬市場が推進されています。

タイプ別卵巣がん治療薬市場 - 2022 年および 2030 年

卵巣がん治療薬市場動向

併用療法

いくつかの医療研究機関が、卵巣がんを治療するための新しい併用薬を開発しています。 2023年9月、ロイヤル・マースデンの研究者らは、進行卵巣がん患者に有効であることが証明された新薬併用療法を発表した。研究者らは、治療に対する反応率が低い稀な形態の卵巣がんである低悪性度漿液性卵巣がん(LGSOC)に対する併用薬物療法の効果を試験した。 RAMP-201臨床試験は、LGSOC患者におけるアブトメチニブ薬とデファクチニブを組み合わせて、それらの相乗的な治療効果を調査することによって実施されました。中間臨床試験の結果では、この併用療法で治療を受けた患者の 45% で腫瘍の大幅な縮小が見られたことが明らかになりました。併用療法によるこのような満足のいく臨床結果は、反応率がわずか 26% であるイギリスで利用可能な標的療法薬であるトラメチニブと比較して、ほぼ 2 倍効果的です。 2024年1月、FDAは乳がんおよび卵巣がん患者の治療を目的としたSH-105配合剤の承認を発表した。したがって、併用療法は、今後数年間で卵巣がん治療薬市場の成長を促進する可能性が高い新しいトレンドとして浮上しています。

地域分析:

卵巣がん治療薬市場レポートの範囲これには、北米、ヨーロッパ、アジア太平洋、南米および中央アメリカ、中東およびアフリカが含まれます。 2022 年、北米が卵巣がん治療薬市場で最大のシェアを獲得しました。この地域の市場の成長は、トップ企業による製品発売数の増加と主要な市場プレーヤーの存在によって推進されています。米国は北米市場に最大の貢献国です。女性の卵巣がんの発生率が上昇しているため、企業と規制当局はそれぞれこの地域で革新的な医薬品の開発と承認を余儀なくされています。また、受託臨床研究機関 (CRO) の数の増加は、北米の卵巣がん治療薬市場の成長を促進しています。

業界の発展と将来の機会:

卵巣がん治療薬市場の予測この市場の利害関係者が成長戦略を計画するのに役立ちます。市場で活動している主要企業による戦略的開発のいくつかを以下に示します。

2022 年 11 月、ImmunoGen はプラチナ耐性成人患者の治療を目的とした ELAHERE (ミルベツキシマブ ソラフタンシン-ジンクス) の FDA 承認を獲得しました。耐性上皮性卵巣がん。 ELAHERE は、FRα 陽性プラチナ抵抗性卵巣がんの患者に対して特に承認されています。この卵巣がんは、利用可能な治療選択肢が限られており、既存の治療薬の臨床転帰が乏しいため、困難な状態です。競争状況と主要企業:

Elli Lilly、AstraZeneca、GSK、Zielab、ImmunoGen (AbbVie)、GeneTech (Roche)、Vivesto、Allarity Therapeutics, Inc.、Aeterna Zentaris、Luye Pharma は、卵巣がん治療薬市場レポートで紹介されている著名な企業です。これらの企業は、世界中で高まる消費者の需要に応えるために、新技術の開発、既存製品のアップグレード、地理的プレゼンスの拡大に重点を置いています。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which region is expected to witness significant demand for ovarian cancer drugs market in the coming years?

Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2022.

Which are the top companies that hold the market share in ovarian cancer drugs market?

Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.

Who are the key players in the ovarian cancer drugs market?

The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.

Which drug class segment held the largest share in the ovarian cancer drugs market?

The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2022.

Which type segment leads the ovarian cancer drugs market?

The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2022.

What is ovarian cancer drugs market?

Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.

What is the market CAGR value of ovarian cancer drugs market during forecast period?

The CAGR value of the ovarian cancer drugs market during the forecasted period of 2022-2030 is 7.7%.

The List of Companies - Ovarian Cancer Drugs Market

  1. Elli Lilly
  2. AstraZeneca
  3. GSK
  4. Zielab
  5. ImmunoGen
  6. GeneTech (Roche)
  7. Vivesto
  8. Allarity Therapeutics, Inc.
  9. Aeterna Zentaris
  10. Luye Pharma

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports